No price history available.
Key financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | KRWm | 76,461 | 100,597 | 141,803 | 180,123 | 242,939 | 336,800 | N/A | N/A |
| Operating profit | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | KRWm | 38,165 | 43,805 | 75,379 | 74,225 | 97,875 | 131,900 | N/A | N/A |
| EPS reported | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
CLASSYS Inc. is a global supplier of sophisticated medical aesthetic devices. Its diverse product range features SCIZER, a non-invasive solution for subcutaneous fat reduction; ULTRAFORMER MPT, which employs focused ultrasound stimulation for skin tissue coagulation to achieve eyebrow lifts; and ULTRAFORMER III, a high-intensity focused ultrasound (HIFU) surgical device designed for tissue coagulation, aiding in eyelid lifting, skin tightening, and improving subcutaneous tissue elasticity across the face (cheeks), abdomen, and thighs, while also diminishing crow's feet, laugh lines, and neck wrinkles. Additional offerings include INTRASURE, a versatile multi-platform solution for aesthetics and healthcare; FORSHAPE, an RF treatment system engineered to boost metabolism, enhance blood circulation, and facilitate tissue recovery; and VOLNEWMER, a monopolar radiofrequency therapeutic equipment used for skin tissue coagulation as a general electrosurgical instrument. The company's portfolio further encompasses CLATUU Alpha, a medical device that progressively reduces subcutaneous fat layers, particularly in areas of excessive accumulation, using low-temperature energy and negative pressure; Ulfit, which utilizes HIFU energy to improve skin elasticity and subcutaneous tissue in the abdomen and thighs; Refit, a medical device combining RF and negative pressure to elevate tissue temperature and blood flow, thereby alleviating pain in treated areas; AQUAPURE, equipped with four distinct handpieces for applications such as acne suction and various forms of pain relief, including muscle pain; and AQUAPURE II, a multi-functional device for comprehensive facial and body care. These products are marketed under the Classys, Cluederm, and SKEDERM brands. CLASSYS serves a broad client base, including clinics, hospitals, and beauty salons. The company was founded in 2007 and is headquartered in Seoul, South Korea.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
CLASSYS Inc. is a global supplier of sophisticated medical aesthetic devices. Its diverse product range features SCIZER, a non-invasive solution for subcutaneous fat reduction; ULTRAFORMER MPT, which employs focused ultrasound stimulation for skin tissue coagulation to achieve eyebrow lifts; and ULTRAFORMER III, a high-intensity focused ultrasound (HIFU) surgical device designed for tissue coagulation, aiding in eyelid lifting, skin tightening, and improving subcutaneous tissue elasticity across the face (cheeks), abdomen, and thighs, while also diminishing crow's feet, laugh lines, and neck wrinkles. Additional offerings include INTRASURE, a versatile multi-platform solution for aesthetics and healthcare; FORSHAPE, an RF treatment system engineered to boost metabolism, enhance blood circulation, and facilitate tissue recovery; and VOLNEWMER, a monopolar radiofrequency therapeutic equipment used for skin tissue coagulation as a general electrosurgical instrument. The company's portfolio further encompasses CLATUU Alpha, a medical device that progressively reduces subcutaneous fat layers, particularly in areas of excessive accumulation, using low-temperature energy and negative pressure; Ulfit, which utilizes HIFU energy to improve skin elasticity and subcutaneous tissue in the abdomen and thighs; Refit, a medical device combining RF and negative pressure to elevate tissue temperature and blood flow, thereby alleviating pain in treated areas; AQUAPURE, equipped with four distinct handpieces for applications such as acne suction and various forms of pain relief, including muscle pain; and AQUAPURE II, a multi-functional device for comprehensive facial and body care. These products are marketed under the Classys, Cluederm, and SKEDERM brands. CLASSYS serves a broad client base, including clinics, hospitals, and beauty salons. The company was founded in 2007 and is headquartered in Seoul, South Korea.
